clinical trial · NCT07780968
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
Esophageal CancerGastroEsophageal CancerGastroesophageal-junction CancerHER2-positive Gastric CancerStomach CancerZanidatamab
brief summary
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA) (HER2+ la/m GEA).
started
Oct 1, 2026
primary completion
Oct 1, 2031
completion
Oct 1, 2031
last updated
Oct 2, 2026
official title
Real-World Utilization, Treatment Patterns, Tolerability, and Effectiveness of Zanidatamab in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma in the United States
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol